SCHEMBL4811658

SCHEMBL4811658

O=C(c1ccc(Br)cc1)C1C(=O)c2ccccc2C1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.72
HTT P42858 3/20 0.72
HBB P68871 2/20 0.72
ALOX15 P16050 1/20 0.72
CYP1A2 P05177 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
KDM4E B2RXH2 3/20 0.56
LMNA P02545 2/20 0.56
NPC1 O15118 2/20 0.52
GAA P10253 1/20 0.52
GSK3B P49841 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 1/20 0.46
SLC25A5 P05141 2/20 0.45
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
ADORA3 P0DMS8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11451081 0.84 MAPT (1.00) MAPTHTTHBBALOX15CYP1A2
SCHEMBL7145735 0.81 MAPT (0.72) MAPTHTTHBBALOX15CYP1A2
SCHEMBL6958511 0.81 MAPT (1.00) MAPTHTTHBBALOX15CYP1A2
SCHEMBL8604882 0.78 MAPT (0.72) MAPTHTTHBBALOX15CYP1A2
SCHEMBL6970354 0.77 MAPT (0.68) MAPTHTTHBBALOX15CYP1A2
SCHEMBL29603379 0.74 MAPT (0.61) MAPTHTTHBBALOX15CYP1A2
SCHEMBL22802233 0.74 MAPT (0.61) MAPTHTTHBBALOX15CYP1A2
SCHEMBL12532253 0.70 MAPT (0.58) MAPTHTTHBBALOX15CYP1A2
SCHEMBL6863960 0.70 HTT (0.66) MAPTHTTHBBALOX15CYP1A2
SCHEMBL8893921 0.69 MAPT (0.65) MAPTHTTHBBALOX15CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
EP-1603885-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2005-12-14 EP disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed
WO-2004080973-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 MAPT 3666/4885HTT 4814/4885HBB 4850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.